TRIM26 and neoplasm: Interestingly, another study indicated TRIM26 to be lowly expressed in four NSCLC cell lines, including A549, and overexpressed TRIM26 significantly reduced the phosphorylation level of AKT and inhibited the expression level of the cell cycle-related regulators Cyclin D1 and Cyclin D3, suggesting that in NSCLC cells, TRIM26 plays an important role by inhibiting the PI3K/AKT signaling pathway to exert its anti-tumor effect on NSCLC cells [72].